|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
MYD88 Mutation Analysis
MessageBi-directional sequencing of exon 5 of the MYD88 gene which includes detection of the common L265P mutation. Testing is approved for specimens from the state of New York.
Test Code
LAB6018
Alias/See Also
Myeloid Differentiation Primary Response 88
CPT Codes
81479x1
Preferred Specimen
•Peripheral blood: 5 mL in EDTA tube.
•Bone marrow: 2 mL in EDTA tube.
•FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
•Fresh tissue: 0.5 - 1 cm3 in RPMI
•Bone marrow: 2 mL in EDTA tube.
•FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
•Fresh tissue: 0.5 - 1 cm3 in RPMI
Instructions
Use cold pack for transport, making sure cold pack is not in direct contact with specimen.
Methodology
Molecular
Report Available
7 days
Clinical Significance
MYD88 mutation is the most common genetic abnormality in the activated B-cell-like (ABC) subtype of diffuse large B-cell lymphoma (DLBCL), detected in 40% of cases. Mutations are rare in the germinal center B-cell-like (GCB) subtype, so mutation analysis can be useful to differentiate between the ABC and GCB subtypes. The L265P mutation is present in >90% of Waldenstrom's macroglobulinemia (WM) and has been associated with increased risk of progression to WM in IgM MGUS patients. MYD88 is also implicated in susceptibility to BTK inhibitors in the treatment of B-cell neoplasms. Testing is available separately or in combination with three other contributory genes in the BTK Inhibitor Primary Susceptibility Panel.
Performing Laboratory
Neogenomics Laboratories
